Open AccessShortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection
Author(s) -
ElShabrawi Mortada H.,
Abdo Alaa M.,
ElKhayat Hisham R.,
Yakoot Mostafa
Publication year - 2018
Publication title -
journal of pediatric gastroenterology and nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 131
eISSN - 1536-4801
pISSN - 0277-2116
DOI - 10.1097/mpg.0000000000001838
Subject(s) - medicine , daclatasvir , sofosbuvir , tolerability , ledipasvir , adverse effect , cohort , hepatitis c virus , gastroenterology , virus , virology , ribavirin
Recently, sofosbuvir and the fixed‐dose combination of sofosbuvir/ledipasvir were approved for the treatment of chronic hepatitis C virus infection in adolescents, criteria being 12 years old and above or weighing at least 35 kg. Here we present the results of a pilot single cohort of 10 consecutive adolescent patients with chronic hepatitis C virus and treated with dual sofosbuvir/daclatasvir therapy for a response‐tailored duration of 8 weeks for those who achieved very rapid virologic response (vRVR) and 12 weeks for those who did not. All patients achieved vRVR at week 2 and completed the shortened 8 weeks course. All patients (10/10) (100% [confidence interval 72.25–100%]) achieved sustained vRVR at week 12 post‐treatment with good tolerability and no serious adverse events. These data could provide support to our suggested response‐tailored protocol of dual therapy with sofosbuvir/daclatasvir in adolescents particularly for shortened duration in those who achieved vRVR. Further larger randomized controlled studies are recommended.